The nation of Zimbabwe has declined a substantial US health deal valued at 367 million US dollars (£272m) spanning five years over the United States' demand for confidential data.
The decision came to light following a official document from December was leaked, which showed Head of State Emmerson Mnangagwa believed the arrangement was "skewed".
A government spokesman has since explained that the US was requesting genetic material for scientific study and profit but was not willing to share the benefits from any future vaccines.
"We must now begin the challenging and unfortunate process of ending our support in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the United States had provided more than $1.9bn for health programmes to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has called for continued dialogue to reach a deal acceptable to all parties so the country's vital HIV programme can proceed.
Broader Background
This development comes after a similar situation in neighbouring Kenya, where a court halted a related deal with the US following legal challenges were filed about the safety of Kenyans' medical information.
Since returning to the presidency recently, US President Donald Trump has reduced overseas assistance and closed the US Agency for International Development (USAID).
USAID had administered aid for the American government, but Trump argued its spending was "wasteful" and his government was pursuing government-to-government deals to enhance openness and responsibility.
Based on statements, 16 nations in Africa have so far agreed to these new agreements, representing more than $18.3bn of fresh investment.
Details of the Declined Deal
The funds for Zimbabwe would have funded "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this collaboration might have yielded immense benefits for Zimbabwean communities, especially the 1.2 million presently on antiretroviral therapy through US-supported programmes," Tremont said.
However, official spokesman Nick Mangwana maintained the arrangement was "unequal".
"Zimbabwe was being asked to share its genetic material and health information for a long time, with no equivalent guarantee of benefiting from any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that could be developed from that provided information," he stated.
"Effectively, our nation would provide the raw materials for scientific discovery without any assurance that the final treatments would be available to our people should a future health crisis emerge."
National Interest and International Frameworks
He also pointed out that the US's withdrawal from the World Health Organization (WHO) and its pursuit of one-on-one health agreements were undermining structures previously established through the global organization.
Mangwana gave as an example its Pathogen Access and Benefit Sharing scheme created to manage potential global health emergencies.
"This framework is designed to guarantee that when a nation contributes its information, the benefits – such as medicines and cures – are distributed fairly, not commercialised exclusively by those with the resources to develop them."
These objections over the US deal "should not be misconstrued as hostility towards the US," Mangwana stressed.
"We are open to ongoing dialogue with our US partners on how subsequent collaboration might be structured in a way that respects the independence and dignity of each country."
Health Experts Response
A leading public health body said it recognised the government's concerns, but recommended that negotiations must proceed given that a large portion of the nation's HIV programmes depended on external financing.
"Where specific concerns exist, including those involving information security or agreement terms, these can frequently be addressed via detailed discussion and mutually agreed protections," it said.
This impasse highlights the complex challenges between accepting crucial international aid and safeguarding national sovereignty in an ever more data-driven world.